162 related articles for article (PubMed ID: 21094903)
1. Structural basis for ligand recognition of incretin receptors.
Underwood CR; Parthier C; Reedtz-Runge S
Vitam Horm; 2010; 84():251-78. PubMed ID: 21094903
[TBL] [Abstract][Full Text] [Related]
2. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
3. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
[TBL] [Abstract][Full Text] [Related]
4. Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.
Moon MJ; Kim HY; Park S; Kim DK; Cho EB; Park CR; You DJ; Hwang JI; Kim K; Choe H; Seong JY
J Biol Chem; 2012 Feb; 287(6):3873-84. PubMed ID: 22105074
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.
Underwood CR; Garibay P; Knudsen LB; Hastrup S; Peters GH; Rudolph R; Reedtz-Runge S
J Biol Chem; 2010 Jan; 285(1):723-30. PubMed ID: 19861722
[TBL] [Abstract][Full Text] [Related]
6. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling.
Malde AK; Srivastava SS; Coutinho EC
J Pept Sci; 2007 May; 13(5):287-300. PubMed ID: 17437246
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor.
Parthier C; Kleinschmidt M; Neumann P; Rudolph R; Manhart S; Schlenzig D; Fanghänel J; Rahfeld JU; Demuth HU; Stubbs MT
Proc Natl Acad Sci U S A; 2007 Aug; 104(35):13942-7. PubMed ID: 17715056
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
[TBL] [Abstract][Full Text] [Related]
9. Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.
Venneti KC; Malthouse JP; O'Harte FP; Hewage CM
Biochim Biophys Acta; 2011 Jul; 1814(7):882-8. PubMed ID: 21539943
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of human incretin receptor missense variants.
Fortin JP; Schroeder JC; Zhu Y; Beinborn M; Kopin AS
J Pharmacol Exp Ther; 2010 Jan; 332(1):274-80. PubMed ID: 19841474
[TBL] [Abstract][Full Text] [Related]
11. Differential Requirement of the Extracellular Domain in Activation of Class B G Protein-coupled Receptors.
Zhao LH; Yin Y; Yang D; Liu B; Hou L; Wang X; Pal K; Jiang Y; Feng Y; Cai X; Dai A; Liu M; Wang MW; Melcher K; Xu HE
J Biol Chem; 2016 Jul; 291(29):15119-30. PubMed ID: 27226600
[TBL] [Abstract][Full Text] [Related]
12. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion.
Cani PD; Holst JJ; Drucker DJ; Delzenne NM; Thorens B; Burcelin R; Knauf C
Mol Cell Endocrinol; 2007 Sep; 276(1-2):18-23. PubMed ID: 17681422
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced diabetes type 2: In silico study involving class B GPCRs.
Latek D; Rutkowska E; Niewieczerzal S; Cielecka-Piontek J
PLoS One; 2019; 14(1):e0208892. PubMed ID: 30650080
[TBL] [Abstract][Full Text] [Related]
14. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
15. Structure of the glucagon receptor in complex with a glucagon analogue.
Zhang H; Qiao A; Yang L; Van Eps N; Frederiksen KS; Yang D; Dai A; Cai X; Zhang H; Yi C; Cao C; He L; Yang H; Lau J; Ernst OP; Hanson MA; Stevens RC; Wang MW; Reedtz-Runge S; Jiang H; Zhao Q; Wu B
Nature; 2018 Jan; 553(7686):106-110. PubMed ID: 29300013
[TBL] [Abstract][Full Text] [Related]
16. Functional elements of the gastric inhibitory polypeptide receptor: Comparison between secretin- and rhodopsin-like G protein-coupled receptors.
Cordomí A; Ismail S; Matsoukas MT; Escrieut C; Gherardi MJ; Pardo L; Fourmy D
Biochem Pharmacol; 2015 Aug; 96(3):237-46. PubMed ID: 26043830
[TBL] [Abstract][Full Text] [Related]
17. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
18. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
Runge S; Thøgersen H; Madsen K; Lau J; Rudolph R
J Biol Chem; 2008 Apr; 283(17):11340-7. PubMed ID: 18287102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
